CBG Atlas

Safety & reporting
AtlasComparisonsCBGV vs CBDV: Untested vs Tested
How we grade evidenceGlossaryCBG Monograph
Side by side

CBGV vs CBDV: Untested vs Tested

Two varins from the same family, with very different files. CBDV went through a proper clinical trial for seizures and failed to beat placebo. CBGV has only ever been studied in cells and mice. Both are non-intoxicating three-carbon "varin" cannabinoids. Established

Grades follow the evidence behind each statement. Legal notes are general and dated, and they are not legal advice; this page makes no therapeutic claim for either compound.

Side by side

AttributeCBGV (cannabigerovarin)CBDV (cannabidivarin)
Varin ofCBGV (cannabigerovarin)CBGCBDV (cannabidivarin)CBD
Molecular formulaCBGV (cannabigerovarin)C₁₉H₂₈O₂ (CAS 55824-11-8)CBDV (cannabidivarin)C₁₉H₂₆O₂ (CAS 24274-48-4)
Intoxicating?CBGV (cannabigerovarin)No · EstablishedCBDV (cannabidivarin)No · Established
Laboratory recordCBGV (cannabigerovarin)Acts on TRPV1 and TRPV2 channels in cell studies (De Petrocellis 2011) · Demonstrated · in vitroCBDV (cannabidivarin)Showed anticonvulsant activity in animals, which led to testing in people
Human recordCBGV (cannabigerovarin)No study in a person · No primary evidenceCBDV (cannabidivarin)Seizures: a Phase 2 trial missed its primary endpoint (Brodie 2021) · Not supported
Figure P · targets side by side
CBGV and CBDV at six targets: what our registry records, and where it records nothing
Six receptor and channel nodes in rows, with one column for CBGV and one for CBDV. At CB1 cannabinoid receptor: CBGV has no graded interaction in our registry; CBDV has no graded interaction in our registry. At CB2 cannabinoid receptor: CBGV has no graded interaction in our registry; CBDV has no graded interaction in our registry. At α2-adrenoceptor: CBGV has no graded interaction in our registry; CBDV has no graded interaction in our registry. At 5-HT1A serotonin receptor: CBGV has no graded interaction in our registry; CBDV has no graded interaction in our registry. At TRPV1 and TRPV2 ion channels: CBGV has no graded interaction in our registry; CBDV has no graded interaction in our registry. At TRPM8 ion channel: CBGV has no graded interaction in our registry; CBDV has no graded interaction in our registry. CBGV and CBDV: no receptor-level record in our registry at any of the six targets; the registry is CBG-centred. Every recorded direction was measured in receptors, cells or tissue, or is quoted from a review; none is an effect in people, and none is a dose.How to read a cellblocksactivatesactivates, then desensitisesdamps activationrecorded in a review, direction qualified by the source, no rung of its ownno graded interaction in our registryCBGVCannabigerovarinCBDVCannabidivarinCB1CBGV: no graded interactionin our registryCBDV: no graded interactionin our registryCB2CBGV: no graded interactionin our registryCBDV: no graded interactionin our registryα2-adrenoceptorCBGV: no graded interactionin our registryCBDV: no graded interactionin our registry5-HT1ACBGV: no graded interactionin our registryCBDV: no graded interactionin our registryTRPV1 · TRPV2CBGV: no graded interactionin our registryCBDV: no graded interactionin our registryTRPM8CBGV: no graded interactionin our registryCBDV: no graded interactionin our registryCBGV and CBDV: no receptor-level record in our registry at any of these six targets.The registry is CBG-centred, and an empty column shows that rather than hides it. Absence of a record is not evidence of no interaction.
How to read a cell
An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
CB1 cannabinoid receptor
CBGV: no graded interaction in our registry. CBDV: no graded interaction in our registry.
CB2 cannabinoid receptor
CBGV: no graded interaction in our registry. CBDV: no graded interaction in our registry.
α2-adrenoceptor
CBGV: no graded interaction in our registry. CBDV: no graded interaction in our registry.
5-HT1A serotonin receptor
CBGV: no graded interaction in our registry. CBDV: no graded interaction in our registry.
TRPV1 and TRPV2 ion channels
CBGV: no graded interaction in our registry. CBDV: no graded interaction in our registry.
TRPM8 ion channel
CBGV: no graded interaction in our registry. CBDV: no graded interaction in our registry.
A dashed frame means the registry holds no graded interaction there, which is not the same as evidence of none. None of this is an effect in people, and none of it is a dose. CBGV and CBDV have no receptor-level record in our registry at any of the six targets: the registry is CBG-centred, and the empty column says so. CBG's record at researcher depth is on the monograph's target map; the receptors themselves are drawn on the ECS map →

What the evidence settles

The resemblance runs to chemistry and stops there. Once the question turns to people, one compound has a result and the other has a blank.

  • Both are varins. Each is the propyl homolog of a better-known cannabinoid: CBGV of CBG, and CBDV of CBD. Established
  • Both are non-intoxicating. A high like THC's is off the table with either one. Established
  • CBGV: laboratory only. Every verified CBGV result comes from cells or mice, including activity at TRPV1 and TRPV2 channels in vitro (De Petrocellis 2011). No study has tested it in a person. No primary evidence
  • CBDV: tested, and not supported for seizures. A Phase 2 randomised controlled trial in adults with focal seizures put CBDV up against placebo, and it did no better on any seizure measure (Brodie 2021). Not supported
  • Untested and tested-and-null are different records. For CBGV, nobody has run the human study. For CBDV the seizure trial happened, and its result counts against the claim. So a seizure claim for CBDV contradicts a trial, while any claim for CBGV simply floats free of human data. Established

Common questions

Is CBGV the same as CBDV?

No, they are two different molecules. Both are three-carbon "varin" cannabinoids, but CBGV is the varin of CBG (C₁₉H₂₈O₂) and CBDV the varin of CBD (C₁₉H₂₆O₂), and their formulas differ by two hydrogens. Established

Has CBGV been tested in people?

No; so far CBGV research has used only cells and mice. The published record holds no human trial, pharmacokinetic study or safety study of CBGV, so there are no human data on what it does or how safe it is. No primary evidence

Does CBDV work for seizures?

It failed in the controlled trial that tested it. That trial, a Phase 2 randomised controlled study in adults with focal seizures, found CBDV unable to separate from placebo (Brodie 2021), and a seizure claim for CBDV has to argue with that result. Not medical advice. Not supported

Do CBGV or CBDV get you high?

No. Both are non-intoxicating, and neither produces the kind of high THC does. Established

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Sources

  • De Petrocellis et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. PMID 21175579.
  • Brodie et al. (2021). A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. PMID 33998885.

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →

Keep exploring

More comparisons